Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211302 · ClinicalTrials.gov registry record · NA
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)
A NA study, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT00211302: Clinical Trial NA study, sponsored by Louisiana State University Health Sciences Center Shreveport.
NCT00211302 is a NA study that was terminated before completion, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211302, a NA study, was terminated before completion, sponsored by Louisiana State University Health Sciences Center Shreveport.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components of the negative symptom array. Further, examination of brain functional activity using functional magnetic resonance imaging (fMRI) during a verbal learning task, as well as behavioral performance and associated electroencephalographic (EEG) data of episodic memory, working memory and intermediate term verbal memory collected with the Sustained Attention and Memory Brain Function Test (SAM-BFT), may also provide data showing the neural correlates of these changes in cognition.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-02 |
| Phase | NA |
Why NCT00211302 stopped before completion
NCT00211302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00211302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211302 about?
NCT00211302 is a clinical study titled "Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)". Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components o...
What is the current status of trial NCT00211302?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2003-08. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00211302?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00211302?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00211302's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia